Background {#Sec1}
==========

Liver tumor initiating cells (TICs), also termed as liver cancer stem cells (CSCs), are the reason of liver tumorigenesis, metastasis, drug resistance and relapse \[[@CR1]\]. Because these cells are in quiescent state and highly express many drug pumps (including ABCG2), liver TICs can survive during drug treatment, and initiate new tumors once drugs are removed \[[@CR2]\]. Liver TICs have self-renewal and differentiate capacities, and can form many cell types along with tumorigenesis \[[@CR3]\]. Based these specific characteristics, several functional systems have been developed for liver TICs, including sphere formation, side population, colony formation, transwell assay and tumor initiation assay \[[@CR4]--[@CR6]\]. Recent years, various surface markers of liver TICs were found, including CD13, CD133, EPCAM, CD24 and CD90 \[[@CR7]--[@CR10]\]. Some transcription factors were also found to participate in the self-renewal regulation of liver TICs, including Sox4, Zic2 and Oct4 \[[@CR6], [@CR11]\]. Although the importance of liver TICs is well-known, the self-renewal regulation of liver TICs are still unclear.

The activation of liver TICs is finely regulated. Wnt/β-catenin, Notch, Hedgehog signaling pathways play critical roles in liver TICs \[[@CR12], [@CR13]\]. G protein coupled receptors (GPCR) are critical modulators in signal transduction \[[@CR14]\]. GPCRs play critical roles in many disease, including tumorigenesis, conferring GPCRs the most widely-used drug-targets \[[@CR15]\]. While, the exact roles of GPCRs in liver TIC self-renewal are still elusive. Here we performed an unbiased screening and found GPR107 was highly expressed in liver cancer and liver TICs. GPR107 plays an essential role in the internalization of pseudomonas aeruginosa exotoxin A and can interacts with neuronostatin \[[@CR16], [@CR17]\]. The role of GPR107 in tumorigenesis hasn't been reported. Here, we found GPR107 was required for the self-renewal of liver TICs and liver tumorigenesis.

Long noncoding RNAs (LncRNAs) are RNA molecules longer than 200 nt but have no coding potential \[[@CR18]\]. LncRNAs were considered as byproductions of transcription process. Recently, the biological roles of lncRNAs are emerging. LncRNAs play critical roles in immunological regulation \[[@CR19]\], development \[[@CR20]\], tumorigenesis \[[@CR21]\] and so on. LncRNAs exert their roles through binding with remodeling complex and recruiting them to the promoter of target genes, and also can interact with proteins to modulate their stabilities or activities \[[@CR22]\]. According to the relative location between lncRNAs and their target genes, two kinds of function pattern of lncRNAs have been discovered: *in cis* and *in trans* \[[@CR23]\]. As one of the common mechanisms, many lncRNAs regulate the transcription activity of nearby genes through recruiting chromatin remodeling complex \[[@CR24]\]. Here we found a lncRNA was located near from *GPR107* locus, and required for the transcription initiation of GPR107.

Methods {#Sec2}
=======

Reagents {#Sec3}
--------

Anti-β-actin (cat. no. A1978) and DAPI (cat. no. 28718--90-3) were from Sigma-Aldrich. Anti-GPR107 (25076--1-AP) antibody was from Proteintech Company. Anti-SRCAP (cat. no. PAB22228) antibody was from abnova. Phycoerythrin (PE)-conjugated CD133 (cat. no. 130098826) was from Miltenyi Biotec. The Chemiluminescent Nucleic Acid Detection Module (cat. no. 89880) and LightShift Chemiluminescent RNA EMSA kit (cat. no. 20158) were from Thermo Scientific. Biotin RNA Labeling Mix (cat. no. 11685597910) and T7 RNA polymerase (cat. no. 10881767001) were from Roche Life Science.

Sphere formation {#Sec4}
----------------

For liver TIC sphere formation assay, 5000 HCC cells were cultured in sphere formation medium (1 × B27, 1 × N2, 20 ng/ml EGF, 20 ng/ml bFGF, in DMEM/F12) and seeded into Ultra Low Attachment six-well plates (cat. no. 3471, Corning). Two weeks later, typical images were taken and sphere numbers were counted. Sphere initiating ratios (%) = Sphere numbers/5000 × 100%.

Primary cell isolation and culture {#Sec5}
----------------------------------

Primary HCC cells were obtained from hepatocellular carcinoma patients, and the information of HCC samples used in this research was listed in Table [1](#Tab1){ref-type="table"}. For primary cell isolation, a portion of excised tumor was incubated in Hanks balanced salt solution (HBSS; Gibco) and transported to the laboratory on ice. Then the samples were cut into small fragments, and digested in HBSS containing 0.03% pronase, 0.05% type IV collagenase, and 0.01% deoxyribonuclease for 30 min at 37 °C. The sample was filtered through 100-μm-nylon filter and centrifuged for 2 min at 50 x g in 4 °C. HCC primary cells were in precipitation, and cell survival & purification were examined. For sphere formation, 5000 primary cells were seeded into sphere formation medium and cultured in Ultra Low Attachment six-well plate. For liver TIC enrichment, HCC primary cells were incubated with CD133 antibody for FACS.Table 1Characteristics of HCC samplesSamplesSample 1Sample 2Sample 3Sample 4Sample 5Age6172537463SexFemaleMaleMaleMaleFemaleHBsAg+++++Serum α-fetoprotein5.8 ng/ml218231684391216Tumor bulk used (mm)7.2 × 6.3 × 5.25.8 × 4.2 × 3.99.2 × 8.3 × 7.57.9 × 5.3 × 4.86.9 × 6.1 × 4.2CirrhosisNoNoYesNoYesVascular invasionNoNoYesYesNoStagesT1T2T3T3T2Sphere formation+**--**+++CD133^+^ cells++**--**++

Liver TIC sorting {#Sec6}
-----------------

For liver TIC sorting, primary cells were incubated in PBS at 5000 cells/μl, supplementary with 2% FBS. Then Phycoerythrin (PE)-conjugated anti-CD133 antibody or control IgG were added (1:100). The samples were placed in 4 °C for 30 min, and then liver TICs were isolated by FACS. BD FACSAria was used for sorting and CD133^+^ cells were liver TICs.

Fluorescence in situ hybridization (FISH) {#Sec7}
-----------------------------------------

For FISH assay, fluorescence-conjugated lncGPR107 probes were generated according to the manual of Biosearch Technologies. HCC samples, liver TICs or oncospheres were treated in a non-denaturing condition, followed by hybridization with lncGPR107 probes. After RNA hybridization, then corresponding antibodies (anti-CD133, Zic2, SRCAP) or fluorescence-conjugated antibodies were added for protein observation. Finally samples were incubated in 4′,6-diamidino-2-phenylindole (DAPI, 1:1000) for 5 min' counterstain, and observed by confocal microscopy (FV1000, Olympus). All experiments were performed according to manuals of Biosearch Technologies.

RNA pulldown {#Sec8}
------------

For RNA pulldown assays, biotin-labeled lncGPR107 or fragments were obtained by in vitro transcription and biotin RNA labeling mix (Roche). Then the labeled RNAs were incubated with liver oncosphere lysate for six hours. Streptavidin beads were added for another three hours' incubation. The samples were washed for three times (five minutes once), and then incubated in loading buffer and boiled at 100 °C for 10 min. Finally the samples were subjected into SDS--PAGE. For protein identification, specific bands enriched by lncGPR107 were identified by mass spectrometry (LTQ Orbitrap XL). For Western blot, the samples in SDS-PAGE were transferred onto NC membrane and detected by antibodies.

Chromatin immunoprecipitation (ChIP) {#Sec9}
------------------------------------

ChIP assays were completed according to Upstate Biotechnology. Briefly, lncGPR107 silenced or lncGPR107 overexpressing spheres were fixed with 1% formaldehyde for 15 min' crosslink, and crushed in SDS lysis buffer. The samples were then treated by ultrasonic for shearing DNA. SRCAP, H3K4Me3, RNA polymerase II or control IgG antibodies were added into samples for 6 h' incubation. Then beads containing sonicated salmon sperm (Upstate Biotechnology) were added into samples for DNA enrichment. DNA segment enrichment of *GPR107* promoter was examined by real-time PCR.

ASO treatment {#Sec10}
-------------

For HCC propagation, primary HCC cells were injected into BALB/c nude mice for tumor propagation. Six weeks later, tumors were obtained for another round tumor propagation (if necessary) until the cells were enough for experiments in 18 mice. For each mice, 1 × 10^6^ cells were used for subcutaneous injection. When tumors were reached to 300 mm^3^ (about three weeks), mice were randomly assigned into three groups (six mice per group). LncGPR107 ASOs or control ASO were injected into tumors every 4 days. Three weeks after ASO intratumoral injection, tumors were obtained, weighted and used for further experiments. GPR107 antibody was used for immunohistochemistry, Ki67 and CD133 antibodies were used for FACS.

GPCR expression analysis {#Sec11}
------------------------

For gene expression analysis, GSE14520 was selected because it contained a large number of HCC samples with detailed clinical information, and download form NCBI database. R language and Bioconductor methods were utilized for background correction, normalization, calculation and annotation. Gene lists and expression levels generated by R3.1.0 were used for further analyses. For G protein coupled receptors (GPCRs) analysis, GPCRs list was download from DAVID website. GPCRs were listed according to expression changes in liver tumorigenesis. The expression levels in every samples were normalized to the average expression of peri-tumor samples, and shown as heatmap.

Tumor propagation and initiating assay {#Sec12}
--------------------------------------

For tumor propagation, 1 × 10^6^ lncGPR107 silenced and control cells were subcutaneously injected into 6-week-old BALB/c nude mice. One month later, tumors were selected and tumor weight was examined. For tumor initiation, 10, 1 × 10^2^, 1 × 10^3^, 1 × 10^4^ and 1 × 10^5^ lncGPR107 silenced and control cells were subcutaneously injected into 6-week-old BALB/c nude mice for 3 months' tumor formation. Tumor formation was observed for tumor-free ratios. Tumor initiating ratios were calculated by Extreme Limiting Dilution Analysis (ELDA) ([http://bioinf.wehi.edu.au/software/elda/](http://bioinf.wehi.edu.au/software/elda)) \[[@CR25]\].

Immunohistochemistry {#Sec13}
--------------------

For immunohistochemistry, formalin-fixed liver cancer sections were treated with xylene and graded alcohols (100, 90% and then 70%) for hydratization. Then the samples were incubated 15 min in 3% H~2~O~2~, followed by 15 min's boiling in citrate buffer. The tissues were incubaed with primary antibody (GPR107, 1:100) and HRP-conjugated secondary antibody. Finally the sections were counterstained with hematoxylin and dehydrated in graded alcohols, followed by observation with Nikon-EclipseTi microscopy.

Realtime PCR {#Sec14}
------------

Total RNA was obtained from primary samples or oncospherss by standard TRIZOL method. Briefly, 1 ml TriZol was added into samples for dissolution through 5 min's incubation. 200ul chloroform was then added into samples and mixed vigorously, followed by separation with 12,000 g centrifugation. The RNA components in supernatant were extracted with isopropanol and then washed with 75% ethanol. RNA pallets were dissolved with RNase-free H~2~O. RT-PCR (revers-transcription PCR) was performed to generate cDNA from RNA, and reatime PCR was performed to examine RNA expression with ABI7300. The primer sequences for realtime PCR were: GPR107, 5'-GGGGCAGTGTCATTTCAGTTT-3′, 5'-CTGAGAGGTAGCTGTCAGGAT-3′. lncGPR107, 5'-GGCTCAGCTACTGAAGCCGG-3′, 5'-AGGGGCCTGGCTGTCCTGCT-3′.

Western blot {#Sec15}
------------

Liver cancer or spheres were crushed with RIPA buffer (0.5% sodium deoxycholate, 1% NP-40, 1 mM EDTA, 0.1% SDS and 50 mM Tris, 150 mM NaCl, pH 8.0) and subjected into SDS--PAGE. The protein samples were transferred onto NC membrane (Beyotime Biotechnology), followed by incubation with primary antibodies and HRP-conjugated secondary antibodies for visualization.

RNA pulldown {#Sec16}
------------

Biotin-labeled lncGPR107 transcript was obtained with in vitro transcription (Roche), and incubated with oncosphere lysate. Then streptavidin conjugated beads were used for pulldown and enriched components were subjected into SDS--PAGE, followed by mass spectra or Western blot analyses.

Statistical analysis {#Sec17}
--------------------

One-tailed Student's t tests were used for statistical analysis. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001. *P* \< 0.05 was defined to be statistically significant. All experiments were repeated at least three times.

Results {#Sec18}
=======

GPR107 was up-regulated in liver cancer and liver TICs {#Sec19}
------------------------------------------------------

Liver tumorigenesis is a long-term and complex process, and many signaling pathways are involved \[[@CR26]\]. Wnt/β-catenin and Notch pathways are well investigated in liver tumorigenesis, and the roles of GPCR signaling in liver tumorigenesis and liver TICs are elusive. Here, we analyzed online-available dataset for GPCR expression. GSE14520 contains more than 400 samples with detailed clinical characteristics, and serves as a good candidate for dataset analysis \[[@CR27], [@CR28]\]. We analyzed the expression profiles of 382 GPCRs and found some GPCRs were highly expressed in liver tumors and some were down-regulated (Fig. [1a](#Fig1){ref-type="fig"}). Here, we focused on GPR107 because it is the most highly expressed GPCR in liver tumor samples (Fig. [1a, b](#Fig1){ref-type="fig"}). Moreover, the expression pattern of GPR107 was associated with liver tumor clinical characteristics, including metastasis, relapse and prognosis (Fig. [1c-e](#Fig1){ref-type="fig"}). We then obtained peri-tumor, early HCC (eHCC) and advanced HCC (aHCC) samples, and examined GPR107 expression with immunohistochemistry, confirming the high expression of GPR107 along with liver tumorigenesis (Fig. [1f](#Fig1){ref-type="fig"}).Fig. 1GPR107 was the most highly expressed GPCR in liver cancer and TICs. **a** The expression profiles of G-protein-coupled receptors in peri-tumor and tumor. GSE14520, containing 215 peri-tumor and 224 tumor samples, was used for analysis. 382 G-protein-coupled receptors in the probeset were shown. Blue and red represent low expression and high expression, respectively. The overviewed expression profile was shown in left panel and the top ten highly expressed GPRs were shown in right panel. **b** GPR107 was highly expressed in tumor samples. **c**, **d** The liver cancer patients were grouped according to metastasis (**c**) or relapse (**d**), followed by GPR107 expression examination. **e** HCC samples were grouped into two subsets according to GPR107 expression levels for Kaplan-Meier survival analysis. **f** Immunohistochemistry of GPR107. 19 peri-tumor, 7 early HCC (eHCC) and 12 advanced HCC (aHCC) were used for GPR107 staining. **g**, **h** GPR107 expression levels in liver TICs (**g**) and oncospheres (**h**) were examined by realtime PCR. GPR107 expression levels in liver non-TICs and non-spheres were normalized as 1. **i**, **j** GPR107 protein levels in liver TICs (**i**) and stem-like spheres (**j**) were examined by Western blot. For **b**, **c**, **d**, data are shown as box-and-whisker plots. Whiskers above and below boxes extend to the 95th and 5th percentiles, respectively. Horizontal lines within boxes denote median levels of gene intensity. For **f**, **g**, **h**, data were shown as means±s.d. Experiments were repeated four times

We then evaluated the expression levels of GPR107 in liver TICs. We obtained HCC primary cells (Table [1](#Tab1){ref-type="table"}), enriched liver TICs with surface marker CD133 and examined GPR107 with realtime PCR, and found GPR107 expression was increased in liver TICs (Fig. [1g](#Fig1){ref-type="fig"}). GPR107 was also highly expressed in oncospheres (Fig. [1h](#Fig1){ref-type="fig"}). The up-regulation of GPR107 in liver TICs was also confirmed by Western blot (Fig. [1i, j](#Fig1){ref-type="fig"}). Overall, GPR107 was up-regulated in liver cancer and liver TICs.

LncGPR107 was overexpressed in liver TICs {#Sec20}
-----------------------------------------

We then focused on *GPR107* loci and found a long noncoding RNA LOC401554 (hereafter termed as lncGPR107). Many lncRNAs are may co-expressed with their neighboring genes \[[@CR20]\], so we examined lncGPR107 expression pattern. LncGPR107 was also highly expressed in liver cancer, especially in advanced liver cancer (Fig. [2a](#Fig2){ref-type="fig"}). Realtime PCR results revealed the positive relationship between the expression levels of GPR107 and lncGPR107 (Fig. [2b](#Fig2){ref-type="fig"}). Northern blot and in situ hybridization validated the high expression of lncGPR107 in liver cancer samples (Fig. [2c, d](#Fig2){ref-type="fig"}).Fig. 2LncGPR107 was highly expressed in liver cancer cells and TICs. **a** Total RNA from 19 peri-tumor, 7 early HCC and 12 advanced HCC was extracted and lncGPR107 expression was detected with realtime PCR. **b** The correlation between GPR107 and lncGPR107 expression levels in tumor samples were shown. **c** RNA sample from peri-tumor and tumor samples were used for lncGPR107 Northern blot, revealing the high expression of lncGPR107 along with liver tumorigenesis. **d** In situ hybridization of lncGPR107. LncGPR107^high^ cell ratios were shown in middle panels and lncGPR107 photon intensity was shown in right panels. **e**, **f** LncGPR107 expression levels in CD133^+^ liver TICs (**e**) and stem-like oncospheres (**f**) were examined through realtime PCR. **g**, **h** Fluorescence in situ hybridization (FISH) analysis for lncGPR107 expression and localization in TIC/non-TIC (**g**) or sphere/non-sphere (**h**). ZIC2 and CD133 were liver TIC markers. Scale bars, 10 μm. Experiments were repeated at least three times

We then analyzed lncGPR107 expression in liver TICs. CD133 positive liver TICs and oncospheres were enriched for lncGPR107 detection, revealing that lncGPR107 was highly expressed in liver TICs (Fig. [2e, f](#Fig2){ref-type="fig"}). Fluorescence in situ hybridization (FISH) assay also confirmed the overexpression of lncGPR107 in liver TICs (Fig. 2g) and oncospheres (Fig. [2h](#Fig2){ref-type="fig"}).

LncGPR107 was required for the self-renewal of liver TICs {#Sec21}
---------------------------------------------------------

Then we examined the role of lncGPR107 in self-renewal regulation of liver TICs. We generated lncGPR107 silenced cells through CRISPRi strategy \[[@CR29]\], and found decreased expression of TIC markers and impaired self-renewal capacity (Fig. [3a, b](#Fig3){ref-type="fig"}). Tumor initiation assays also confirmed the impaired tumor initiation and decreased liver TIC ratios of lncGPR107 depleted cells (Fig. [3c](#Fig3){ref-type="fig"}). Tumor invasion was an important characteristic of liver TICs, and thus we examined the invasion capacity through transwell assay, and found impaired invasion of lncGPR107 depleted cells (Fig. [3d](#Fig3){ref-type="fig"}). We also generated lncGPR107 silenced cells through antisense oligo (ASO), and also found impaired self-renewal (Fig. [3e](#Fig3){ref-type="fig"}) and invasion (Fig. [3f](#Fig3){ref-type="fig"}).Fig. 3LncGPR107 played an essential role in liver TIC self-renewal. **a** LncGPR107 were depleted through CRISPRi strategy, and the expression levels of TIC marker were examined by realtime PCR. **b** LncGPR107 depleted and control cells were used for sphere formation detection. Sphere photos and sphere formation ratios were shown in left and right panels, respectively. **c** 10, 1 × 10^2^, 1 × 10^3^, 1 × 10^4^ and 1 × 10^5^ lncGPR107 depleted cells were injected into BALB/c nude mice. Three month later, tumor-free mice were observed and liver TIC ratios were calculated through ELDA analysis (lower panels). *n* = 6 for each group. **d** 3 × 10^5^ lncGPR107 depleted cells were seeded onto Matrigel-coated membrane, and tumor invasion was observed 36 h later. **e**, **f** HCC primary cells were treated with lncGPR107 antisense oligo (ASO), followed by sphere formation (**e**) and tumor invasion (**f**) detection. **g** LncGPR107 was activated in primary cells through CRISPRa strategy, followed by realtime PCR detection for indicated genes. **h** LncGPR107 activated and control cell were used for sphere formation assay. Representative images and sphere-initiating ratios were shown. **i** 10, 1 × 10^2^, 1 × 10^3^, 1 × 10^4^ and 1 × 10^5^ lncGPR107 activated cells were injected into nude mice for 3 months' tumor initiation, and tumor-free ratios were shown. *n* = 6 for each group. Experiments were repeated four times

We the activated lncGPR107 expression using CRISPRa strategy and found increased expression of liver TICs (Fig. [3g](#Fig3){ref-type="fig"}) \[[@CR29]\]. LncGPR107 activation also enhanced sphere formation indicating the sufficient role of lncGPR107 in liver TIC (Fig. [3h](#Fig3){ref-type="fig"}). Through tumor initiation assay, enhanced tumor initiation capacities of lncGPR107 activated cells were also confirmed (Fig. [3i](#Fig3){ref-type="fig"}). Altogether, lncGPR107 played a necessary and sufficient role in liver TIC self-renewal.

LncGPR107 positively regulated the self-renewal of liver TICs through GPR107 {#Sec22}
----------------------------------------------------------------------------

Many lncRNAs participated in the transcription regulation of nearby genes. To explore the target genes of lncGPR107, we firstly examined the expression of GPR107. As expected, lncGPR107 depletion largely impaired the expression of GPR107, and lncGPR107 overexpression promoted GPR107 expression (Fig. [4a-c](#Fig4){ref-type="fig"}).Fig. 4LncGPR107 drove the expression of GPR107. **a** GPR107 expression levels in lncGPR107 ASO treated cells were detected through realtime PCR. **b**, **c** GPR107 expression levels in lncGPR107 depleted cells (**b**) or lncGPR107 overexpressing cells (**c**) were examined by Western blot. β-actin was a loading control. **d** GPR107 deleted cells were established through CRISPR/Cas9 for sphere formation. Western blot was performed for deletion confirmation (left panels). Typical sphere images and sphere initiating cell ratios were shown in middle and right panels, respectively. **e** 10, 1 × 10^2^, 1 × 10^3^, 1 × 10^4^ and 1 × 10^5^ GPR107 deficient cells were used for 3 months' tumor initiation. The ratios of tumo-free mice were shown in left panels and TICs ratios were shown in right panels. *n* = 6 for each group. **f**, **g** LncGPR107 was silenced (**f**) or overexpressed (**g**) in GPR107 deleted cells, and sphere formation assay was performed. **h**, **i** Transwell assay of the indicated cells revealed that lncGPR107 had impaired role upon GPR107 knockout. Experiments were repeated three times

To explored the role of GPR107 in liver TIC regulation, we generated GPR107 knockout cells, and discovered impaired sphere formation of GPR107 deficient cells (Fig. [4d](#Fig4){ref-type="fig"}). Tumor initiation assay also indicated the essential role of GPR107 in liver tumor initiation (Fig. [4e](#Fig4){ref-type="fig"}). Our results indicated that GPR107 was overexpressed in liver TIC and played an essential role in the self-renewal regulation of liver TICs.

We then investigated whether lncGPR107 regulated liver TIC through GPR107 expression. We generated lncGPR107 knockdown cells using GPR107 deficient cells, and found upon GPR107 deletion, lncGPR107 had no role in the self-renewal of liver TICs (Fig. [4f](#Fig4){ref-type="fig"}). LncGPR107 overexpression also showed no influence in sphere formation upon GPR107 knockout (Fig. [4g](#Fig4){ref-type="fig"}). Using transwell invasion assay, we also confirmed that GPR107 was necessary for the function of lncGPR107 (Fig. [4h, I](#Fig4){ref-type="fig"}). Altogether, lncGPR107 drove the self-renewal of live TICs through GPR107.

LncGPR107 recruited SRCAP complex to *GPR107* promoter to drove its expression {#Sec23}
------------------------------------------------------------------------------

To further explore the molecular mechanism of lncGPR107, we performed RNA pulldown assay and silver staining. A specific band in lncGPR107 eluate was identified as SCRCAP by Mass spectrum (Fig. [5a](#Fig5){ref-type="fig"}). Western blot assay also validated the interaction of lncGPR107 and SRCAP (Fig. [5b](#Fig5){ref-type="fig"}). Through region mapping and RNA pulldown assay, the eighth region of lncGPR107 was found to bind SRCAP (Fig. [5c](#Fig5){ref-type="fig"}). RNA Electrophoretic Mobility Shift Assay (EMSA) confirmed the interaction of SRCAP and lncGPR107 (Fig. [5d](#Fig5){ref-type="fig"}). Meanwhile, the binding of SRCAP and lncGPR107 was also validated by RNA immunoprecipitation and FISH assays (Fig. [5e, f](#Fig5){ref-type="fig"}). In conclusion, lncGPR107 interacted with SRCAP in liver TICs.Fig. 5LncGPR107 recruited SRCAP to *GPR107* promoter. **a** Biotin labeled lncGPR107 was generated through in vitro transcription, and incubated with oncosphere lysate for RNA pulldown, and the denoted band of lncGPR107 was identified as SRCAP by Mass spectrum. **b** The binding of lncGPR107 and SRCAP was confirmed by RNA pulldown and Western blot. **c** LncGPR107 truncates were generated (left panel) for RNA pulldown assay (right panel). **d** RNA electrophoretic mobility shift assay indicated the interaction of SRCAP and lncGPR107. The \#8 region of lncGPR107 was used for RNA ESMA. **e** RNA immunoprecipitation (RIP) assay was performed with SRCAP antibody, and the enrichment of lncGPR107 was examined through realtime PCR. The oncospheres derived from HCC sample were used for RIP assay. **f** LncGPR107 and SRCAP subcellular location was examined through double fluorescence in situ hybridization (double-FISH) assay. Oncospheres were used for FISH, confirming the co-localization of SRCAP and lncGPR107 in oncospheres. Scale bars, 10 μm. **g**, **h** SRCAP ChIP assays were performed and *GPR107* promoter enrichment was examined through realtime PCR. LncGPR107 depleted cells (**g**) and lncGPR107 overexpressed cells (**h**) were used for ChIP assays. Experiments were repeated at least three times

SRCAP plays a critical role in chromatin remodeling and transcription regulation \[[@CR30]\]. Accordingly, we examined if lnGPR107 and SRCAP in the activation of GPR107 promoter. ChIP assay confirmed the interaction between SRCAP and *GPR107* promoter (Fig. [5g](#Fig5){ref-type="fig"}). In lncGPR107 depleted cells, impaired binding of SRCAP and *GPR107* promoter was found, again confirming the critical role of lncGPR107 in recruiting SRCAP to *GPR107* promoter (Fig. [5g](#Fig5){ref-type="fig"}). Along with SRCAP, the enrichment of H3K4me3 and RNA polymerase II was also impaired in lncGPR107 depleted cells, confirming the essential role of lncGPR107 in the activation of *GPR107* promoter (Fig. [5g](#Fig5){ref-type="fig"}). LncGPR107 overexpression showed enhanced SRCAP recruiting and stronger activity of *GPR107* promoter (Fig. [5h](#Fig5){ref-type="fig"}). Altogether, lncGPR107 recruited SRCAP complex to *GPR107* promoter to drive its transcription activation.

LncGPR107-SRCAP-GPR107 signaling was required for liver TIC targeting {#Sec24}
---------------------------------------------------------------------

We then examined the role of lncGPR107-SRCAP-GPR107 in liver tumor propagation and targeting. Firstly, we examined tumor propagation of lncGPR107 depleted cells, and found decreased tumor volume upon lncGPR107 inhibition (Fig. [6a](#Fig6){ref-type="fig"}). On the contrary, lncGPR107 overexpression promoted tumor propagation (Fig. [6b](#Fig6){ref-type="fig"}). SRCAP and GPR107 deleted cells were also generated for liver tumor propagation, and smaller tumors were generated upon SRCAP knockout or GPR107 knockout (Fig. [6c](#Fig6){ref-type="fig"}).Fig. 6LncGPR107-SRCAP-GPR107 can be targeted for liver TIC elimination. **a** 1 × 10^6^ primary cells were injected into BALB/c nude mice. When the volume of tumors were reach about 250 mm^3^, lncGPR107 ASO (antisense oligo) and control ASO were injected into tumors every two days. Tumor weight was measured one month later. *n* = 6 for each group. **b** 1 × 10^6^ lncGPR107 overexpressing cells were used for tumor propagation. *n* = 6 for each group. **c** 1 × 10^6^ indicated cells were used for tumor propagation, and the tumors were weighted one month later. *n* = 6 for each group. **d** The indicated tumors were obtained and GPR107 expression was examined through immunohistochemistry. Scale bars, 100 μm. **e**, **f** The indicated tumors were obtained and separated into individual cells for FACS. Ki67^+^ cells (**e**) and CD133^+^ liver TICs (**f**) were examined. *n* = 6 for each group, and the ratios of Ki67^+^ and CD133^+^ cells were shown as means±s.d. Experiments were repeated three times

We then collected the established tumors, examined GPR107 expression and found impaired GPR107 expression upon inhibition of lncGPR107-SRCAP-GPR107 signaling (Fig. [6d](#Fig6){ref-type="fig"}). FACS examination also confirmed that blockade of lncGPR107-SRCAP-GPR107 resulted in a decreased ratios of proliferating cells (Fig. [6e](#Fig6){ref-type="fig"}) and liver TICs (Fig. [6f](#Fig6){ref-type="fig"}), confirming the critical role of lncGPR107-SRCAP-GPR107 pathway in liver tumorigenesis and TIC self-renewal.

Discussion {#Sec25}
==========

With tumor initiation and self-renewal capacities, liver TICs (liver CSCs) are the origin of liver tumor formation, metastasis, relapse and drug resistance \[[@CR3]\]. Several signaling pathways have been reported in the self-renewal regulation of liver TICs, including Wnt/β-catenin, Notch, Hedgehog and Yap1 signaling \[[@CR12], [@CR13], [@CR31]--[@CR33]\]. However, the role of G-protein-coupled receptor (GPCR) signaling in liver TICs hasn't been explored. Here, we analyzed the expression level of GPCRs using online-available HCC dataset and found GPR107 was the most highly expressed GPCRs along with liver tumorigenesis. Moreover, GPR107 is required for the self-renewal of liver TIC, revealing the relationship of liver TICs and GPCR signaling. Besides GPR107, several other GPRs, including OPN3, GPR88, LGR5, PTH2R, ACKR3 F2RL1, GABBR2, PTCFT and GPR5B, are also highly expressed in liver cancers (Fig. [1a](#Fig1){ref-type="fig"}). As one of the most important pathways in signal transduction, it is possible that more than one GPCR member participate in the self-renewal of liver TIC and liver tumorigenesis. Here, we revealed that GPR107 and lncGRP107 was highly expressed in liver cancer, especially in liver TICs (Fig. [1](#Fig1){ref-type="fig"} and Fig. [2](#Fig2){ref-type="fig"}). In peri-tumor, the expression levels of GPR107 and lncGRP107 were extremely low, and very few cells showed modest expression of GPR107 and lncGRP107 (Figs. [1f](#Fig1){ref-type="fig"} and [2d](#Fig2){ref-type="fig"}). These GPR107 and lncGRP107 expressed cells may also have self-renewal and propagating capacities. Some groups identified liver progenitor cells in normal tissue, with self-renewal and differentiating capacities \[[@CR34], [@CR35]\]. It's an interesting issue to investigate whether liver progenitor cells also show GPR107/lncGRP107 expression and the potential role of GPR107/lncGRP107 in liver progenitor cells.

Recently, GPCR signaling was found to be related to NFkB signaling \[[@CR36]\] and Yap/Taz signaling \[[@CR37]\], which regulated the activation of liver TICs. NFkB and Yap signaling pathways also participated in liver tumorigenesis \[[@CR31]\]. Here we found GPR107 was overexpressed in and required for liver TICs, how GPR107 functions is still unclear. It'll be interesting to detect the role of GPR107 in the activation of NFkB signaling and Yap/Taz signaling.

LncRNAs were recognized as the byproduct of RNA polymerase II, while, their critical roles emerge recently. Several lncRNAs regulate the transcription activation *in cis*. For example, lncTCF7 recruits SWI/SNF complex to activate TCF7 expression, and finally drives the self-renewal of liver TICs \[[@CR24]\]. Our results provided another example for *in cis* regulation of lncRNA. Interestingly, lncGPR107 also recruited chromatin remodeling complex to the promoter of target gene. Through this regulation mechanism, lncGPR107 was co-expressed with GPR107 in liver TICs. LncGPR107 participated in the self-renewal of liver TICs through facilitating the transcriptional activation of GPR107. Through loss-of-function assays, GPR107 was also involved in the self-renewal of liver TICs.

To some extent, tumorigenesis is a process of chromatin remodeling \[[@CR38]\]. Chromatin remodeling is mediated by chromatin remodeling complexes, including SWI/SNF, NURD, NURF, PRC1/2 and SRCAP complexes \[[@CR39]--[@CR41]\]. Usually, the key components of many chromatin remodeling complexes are dys-regulated along with tumorigenesis. For example, two components of SWI/SNF (BRG1 and BRM) were differently expressed during liver tumorigenesis. BRG1 was highly expressed and BRM was lowly expressed in liver cancer and liver TICs \[[@CR31]\]. EZH2, the core component of PRC2 complex, was also highly expressed in liver tumorigenesis \[[@CR32]\]. Here, we found SRCAP was required for GPR107 expression, and the binding of SRCAP complex and *GPR107* promoter is lncGPR107-dependent.

Conclusion {#Sec26}
==========

The role of GPCRs in liver TIC self-renewal remain unclear. Here, we found GPR107 was the most highly expressed GPCR in liver cancer and liver TICs. LncGPR107 participated in the transcriptional regulation of GPR107 in cis, through recruiting SRCAP remodeling complex to *GPR107* promoter. This work revealed the important role of GPCR signaling in liver TIC self-renewal and added a new layer for liver TIC and GPCR regulation.

ASO

:   Antisense oligo

ChIP

:   Chromatin immunoprecipitation

EMSA

:   Electrophoretic mobility shift assay

GPCR

:   G protein coupled receptor

HCC

:   Hepatocellular carcinoma

lncRNA

:   long noncoding RNA

TIC

:   Tumor initiating cell
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